SAROGLITAZAR

SynDRA canonical compound SYN0039675 — structure-anchored drug synonym record

Clinical phase	Launched
Primary target(s)	ANGPTL4 \| PPARA \| PPARG
Mechanism of action	PPAR receptor agonist
Indication	diabetes mellitus \| dyslipidemia \| non-alcoholic steatohepatitis (NASH)
Disease area	cardiology \| endocrinology \| gastroenterology

All known targets

lipaglyn
ZYH1
saroglitazar magnesium
Lipaglyn
UNII-E0YMX3S4JD
E0YMX3S4JD
Saroglitazar magnesium
(S)-2-Ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid
Saroglitazar [INN]
saroglitazarum
SCHEMBL16346340
DTXSID10197819
MRWFZSLZNUJVQW-DEOSSOPVSA-N
CHEBI:134708
AKOS027337115
CS-6149
DB13115
HY-19937
(2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid
(S)-alpha-ethoxy-4-[2-[-methyl-5-[4-(methylthio) phenyl]-1H-pyrrol-1-yl]ethox
RefChem:181452
DTXCID20120310
C25H29NO4S
MFCD28502034
Bilypsa
Saroglitazar (USAN/INN)
SAROGLITAZAR [USAN]
SAROGLITAZAR [WHO-DD]
orb1708588
GTPL14341
EX-A7122
VUA39909
BDBM50615692
s9674
AC-37949
MS-27899
DB-404351
NS00073432